Triplet demonstrates activity in metastatic colorectal cancer

The combination of panitumumab, ipilimumab and nivolumab induced responses among patients with metastatic colorectal cancer, according to phase 2 study results presented at Gastrointestinal Cancers Symposium.The study, which included patients with KRAS, NRAS and BRAF wild-type and microsatellite-stable tumors, provides evidence that combinations of immunotherapies with anti-EGFR therapy are rational and merit further investigation, according to Michael Sangmin Lee, MD, assistant professor at The University of Texas MD Anderson Cancer Center.“Standard-of-care options for patients in theRead More

Share on facebook
Share on twitter
Share on linkedin